389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy

MLA

Montaser Shaheen, et al. “389 Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.” Journal for ImmunoTherapy of Cancer, vol. 9, Nov. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2113b83663c0d15006bc607da094b55b&authtype=sso&custid=ns315887.

APA

Montaser Shaheen, Lynn M. Schuchter, Delvys Rodriguez-Abreu, Erin L. Filbert, Maria Gonzalez-Cao, Apar Kishor Ganti, Ralph J. Hauke, Enriqueta Felip, Nicholas Iannotti, Ana Arance, Sarah A. Weiss, Harriet M. Kluger, Valentina Boni, Mario Sznol, Alfonso Berrocal, Miguel-Ángel Berciano-Guerrero, & Gerald P. Linette. (2021). 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer, 9.

Chicago

Montaser Shaheen, Lynn M. Schuchter, Delvys Rodriguez-Abreu, Erin L. Filbert, Maria Gonzalez-Cao, Apar Kishor Ganti, Ralph J. Hauke, et al. 2021. “389 Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.” Journal for ImmunoTherapy of Cancer 9 (November). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2113b83663c0d15006bc607da094b55b&authtype=sso&custid=ns315887.